Innovent, Takeda ink USD 11.4 billion deal
Chinese drugmaker Innovent Biologics has signed a partnership with Japan’s Takeda Pharmaceutical worth up to USD 11.4 billion to co-develop and commercialize two cancer therapies. The deal includes USD 1.2 billion upfront, as much as USD 10.2 billion in milestone payments, and a USD 100 million equity investment.